Progenics Pharmaceuticals (Progenics Pharmaceuticals) Change In Working Capital : $-3.90 Mil (TTM As of Mar. 2020)

View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Change In Working Capital?

Progenics Pharmaceuticals's change in working capital for the quarter that ended in Mar. 2020 was $7.81 Mil.

Progenics Pharmaceuticals's change in working capital for the fiscal year that ended in Dec. 2019 was $-14.11 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Progenics Pharmaceuticals Change In Working Capital Historical Data

The historical data trend for Progenics Pharmaceuticals's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Change In Working Capital Chart

Progenics Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Change In Working Capital

Get a 7-Day Free Trial

-6.00

6.53

0.23

-1.96

-14.11

Progenics Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Change In Working Capital	Get a 7-Day Free Trial															-2.40	-3.07	0.29	-8.93	7.81

Progenics Pharmaceuticals Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.90 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Progenics Pharmaceuticals Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Progenics Pharmaceuticals (Progenics Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (NAS:PGNX) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007

Website

http://www.progenics.com

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Executives

Asha Das	officer: Chief Medical Officer	C/O PROGENICS PHARMACEUTICALS, INC., 1 WORLD TRADE CENTER, 47TH FL, SUITE J, NEW YORK NY 10007
Ann L. Macdougall	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Karen Jean Ferrante	director	150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Heinz Christoph Maeusli	director	SCHUETZENWEG 3, ENGELBURG V8 9032
Gerard Ber	director	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Eric J Ende	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Bradley L Campbell	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Balaji Venkataraman	10 percent owner, other: See Explanation of Responses	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Virinder Nohria	10 percent owner, other: See Explanation of Responses	1055 POWERS PLACE, SUITE B, ALPHARETTA GA 30009
Nicole Williams	director
David A Scheinberg	director	325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Michael D Kishbauch	director	18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Broadfin Healthcare Master Fund Ltd	10 percent owner	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler	10 percent owner	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc	10 percent owner	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022